These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 31644496)

  • 1. The Association Between Cytomegalovirus Infection and Cardiac Allograft Vasculopathy in the Era of Antiviral Valganciclovir Prophylaxis.
    Klimczak-Tomaniak D; Roest S; Brugts JJ; Caliskan K; Kardys I; Zijlstra F; Constantinescu AA; Voermans JJC; van Kampen JJA; Manintveld OC
    Transplantation; 2020 Jul; 104(7):1508-1518. PubMed ID: 31644496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytomegalovirus infection and allograft rejection among pediatric heart transplant recipients in the era of valganciclovir prophylaxis.
    Das BB; Prusty BK; Niu J; Sue PK
    Pediatr Transplant; 2020 Dec; 24(8):e13750. PubMed ID: 32573886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytomegalovirus infection in heart transplantation: A single center experience.
    Echenique IA; Angarone MP; Rich JD; Anderson AS; Stosor V
    Transpl Infect Dis; 2018 Aug; 20(4):e12896. PubMed ID: 29602266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-center experience with use of letermovir for CMV prophylaxis or treatment in thoracic organ transplant recipients.
    Aryal S; Katugaha SB; Cochrane A; Brown AW; Nathan SD; Shlobin OA; Ahmad K; Marinak L; Chun J; Fregoso M; Desai S; King C
    Transpl Infect Dis; 2019 Dec; 21(6):e13166. PubMed ID: 31487755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diminished impact of cytomegalovirus infection on graft vasculopathy development in the antiviral prophylaxis era - a retrospective study.
    Goekler J; Zuckermann A; Kaider A; Angleitner P; Osorio-Jaramillo E; Moayedifar R; Uyanik-Uenal K; Kainz FM; Masetti M; Laufer G; Aliabadi-Zuckermann AZ
    Transpl Int; 2018 Aug; 31(8):909-916. PubMed ID: 29577455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Randomized Study of Quantiferon CMV-directed Versus Fixed-duration Valganciclovir Prophylaxis to Reduce Late CMV After Lung Transplantation.
    Westall GP; Cristiano Y; Levvey BJ; Whitford H; Paraskeva MA; Paul E; Peleg AY; Snell GI
    Transplantation; 2019 May; 103(5):1005-1013. PubMed ID: 30247316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of cytomegalovirus infection in the development of cardiac allograft vasculopathy after heart transplantation.
    Delgado JF; Reyne AG; de Dios S; López-Medrano F; Jurado A; Juan RS; Ruiz-Cano MJ; Dolores Folgueira M; Gómez-Sánchez MÁ; Aguado JM; Lumbreras C
    J Heart Lung Transplant; 2015 Aug; 34(8):1112-9. PubMed ID: 25940077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytomegalovirus infection and disease reduce 10-year cardiac allograft vasculopathy-free survival in heart transplant recipients.
    Johansson I; Andersson R; Friman V; Selimovic N; Hanzen L; Nasic S; Nyström U; Sigurdardottir V
    BMC Infect Dis; 2015 Dec; 15():582. PubMed ID: 26703239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prophylaxis versus preemptive anti-cytomegalovirus approach for prevention of allograft vasculopathy in heart transplant recipients.
    Potena L; Grigioni F; Magnani G; Lazzarotto T; Musuraca AC; Ortolani P; Coccolo F; Fallani F; Russo A; Branzi A
    J Heart Lung Transplant; 2009 May; 28(5):461-7. PubMed ID: 19416774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Clinical Rejection Versus Rejection on Protocol Biopsy With Cardiac Allograft Vasculopathy in Pediatric Heart Transplant Recipients.
    Asimacopoulos EP; Garbern JC; Gauvreau K; Blume ED; Daly KP; Singh TP
    Transplantation; 2020 Jan; 104(1):e31-e37. PubMed ID: 31568274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of donor and recipient cytomegalovirus serology on long-term survival of lung transplant recipients.
    Mabilangan C; Preiksaitis J; Cervera C;
    Transpl Infect Dis; 2018 Oct; 20(5):e12964. PubMed ID: 29981174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-life use of letermovir prophylaxis for cytomegalovirus in heart transplant recipients.
    Saltiel G; Faure E; Assaf A; Chopin MC; Moreau F; Faure K; Goeminne C; Vuotto F
    Clin Transplant; 2024 May; 38(5):e15327. PubMed ID: 38686437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Less renal allograft fibrosis with valganciclovir prophylaxis for cytomegalovirus compared to high-dose valacyclovir: a parallel group, open-label, randomized controlled trial.
    Reischig T; Kacer M; Hruba P; Hermanova H; Hes O; Lysak D; Kormunda S; Bouda M
    BMC Infect Dis; 2018 Nov; 18(1):573. PubMed ID: 30442095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicenter evaluation of efficacy and safety of low-dose versus high-dose valganciclovir for prevention of cytomegalovirus disease in donor and recipient positive (D+/R+) renal transplant recipients.
    Heldenbrand S; Li C; Cross RP; DePiero KA; Dick TB; Ferguson K; Kim M; Newkirk E; Park JM; Sudaria-Kerr J; Tichy EM; Ueda KR; Weng R; Wisniewski J; Gabardi S
    Transpl Infect Dis; 2016 Dec; 18(6):904-912. PubMed ID: 27639246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytomegalovirus infection in living donor liver transplant recipients significantly impacts the early post-transplant outcome: A single center experience.
    Yadav SK; Saigal S; Choudhary NS; Saha S; Sah JK; Saraf N; Kumar N; Goja S; Rastogi A; Bhangui P; Soin AS
    Transpl Infect Dis; 2018 Aug; 20(4):e12905. PubMed ID: 29668120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Preemptive Therapy vs Antiviral Prophylaxis on Cytomegalovirus Disease in Seronegative Liver Transplant Recipients With Seropositive Donors: A Randomized Clinical Trial.
    Singh N; Winston DJ; Razonable RR; Lyon GM; Silveira FP; Wagener MM; Stevens-Ayers T; Edmison B; Boeckh M; Limaye AP
    JAMA; 2020 Apr; 323(14):1378-1387. PubMed ID: 32286644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased risk of breakthrough infection among cytomegalovirus donor-positive/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis.
    Stevens DR; Sawinski D; Blumberg E; Galanakis N; Bloom RD; Trofe-Clark J
    Transpl Infect Dis; 2015 Apr; 17(2):163-73. PubMed ID: 25661673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical features and outcomes of delayed-onset primary cytomegalovirus disease in cardiac transplant recipients.
    Kijpittayarit-Arthurs S; Eid AJ; Kremers WK; Pedersen RA; Dierkhising RA; Patel R; Razonable RR
    J Heart Lung Transplant; 2007 Oct; 26(10):1019-24. PubMed ID: 17919622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of Low- Versus High-dose Valganciclovir for Prevention of Cytomegalovirus Disease in High-risk Renal Transplant Recipients.
    Gabardi S; Asipenko N; Fleming J; Lor K; McDevitt-Potter L; Mohammed A; Rogers C; Tichy EM; Weng R; Lee RA
    Transplantation; 2015 Jul; 99(7):1499-505. PubMed ID: 25643140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytomegalovirus disease among donor-positive/recipient-negative lung transplant recipients in the era of valganciclovir prophylaxis.
    Mitsani D; Nguyen MH; Kwak EJ; Silveira FP; Vadnerkar A; Pilewski J; Crespo M; Toyoda Y; Bermudez C; Clancy CJ
    J Heart Lung Transplant; 2010 Sep; 29(9):1014-20. PubMed ID: 20598582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.